A time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiforme
Tumors consist of cells in different stages of transformation with molecular and cellular heterogeneity. By far, heterogeneity is the hallmark of glioblastoma multiforme (GBM), the most malignant and aggressive type of glioma. Most proteomic studies aim in comparing tumors from different patients, b...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00183/full |
id |
doaj-9c601f3bfbda4e4985681eb4471089ce |
---|---|
record_format |
Article |
spelling |
doaj-9c601f3bfbda4e4985681eb4471089ce2020-11-24T23:02:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2016-08-01610.3389/fonc.2016.00183207106A time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiformePriscila Ferreira Aquino0Paulo Costa Carvalho1Paulo Costa Carvalho2Fabio C.S. Nogueira3Clovis Orlando Fonseca4Júlio Cesar Thomé de Souza Silva5Maria da Gloria Costa Carvalho6Gilberto Barbosa Domont7Nilson I. T. Zanchin8Juliana de Saldanha da Gama Fischer9Instituto Leônidas e Maria Deane, Fiocruz AmazonasCarlos Chagas Institute, Fiocruz - ParanáInstituto Oswaldo CruzFederal University of Rio de JaneiroFluminense Federal UniversityIpanema Federal HospitalUniversity Hospital Clementino Fraga Filho, Federal University of Rio de JaneiroFederal University of Rio de JaneiroCarlos Chagas Institute, Fiocruz - ParanáCarlos Chagas Institute, Fiocruz - ParanáTumors consist of cells in different stages of transformation with molecular and cellular heterogeneity. By far, heterogeneity is the hallmark of glioblastoma multiforme (GBM), the most malignant and aggressive type of glioma. Most proteomic studies aim in comparing tumors from different patients, but here we dive into exploring the intratumoral proteome diversity of a single GBM. For this, we profiled tumor fragments from the profound region of the same patient’s GBM but obtained from two surgeries a year’s time apart. Our analysis also included GBM‘s fragments from different anatomical regions. Our quantitative proteomic strategy employed 4-plex iTRAQ peptide labeling followed by a four-step strong cation chromatographic separation; each fraction was then analyzed by reversed-phase nano-chromatography coupled on-line with an Orbitrap-Velos mass spectrometer. Unsupervised clustering grouped the proteomic profiles into four major distinct groups and showed that most changes were related to the tumor’s anatomical region. Our analysis revealed that most changes are related to the tumor’s anatomical region. Nevertheless, we report differentially abundant proteins from GBM’s fragments of the same region but obtained one year apart. We discuss several key proteins (e.g., S100A9) and enriched pathways linked with GBM such as the Ras pathway, RHO GTPases activate PKNs, and those related to apoptosis, to name a few. As far as we know, this is the only report that compares GBM fragments proteomic profiles from the same patient. Ultimately, our results fuel the forefront of scientific discussion on the importance in exploring the richness of subproteomes within a single tissue sample for a better understanding of the disease, as each tumor is unique.http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00183/fullQuantitative ProteomicsGlioblastoma Multiformemass spectrometry based proteomicsmolecular heterogeneityiTRAQ. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Priscila Ferreira Aquino Paulo Costa Carvalho Paulo Costa Carvalho Fabio C.S. Nogueira Clovis Orlando Fonseca Júlio Cesar Thomé de Souza Silva Maria da Gloria Costa Carvalho Gilberto Barbosa Domont Nilson I. T. Zanchin Juliana de Saldanha da Gama Fischer |
spellingShingle |
Priscila Ferreira Aquino Paulo Costa Carvalho Paulo Costa Carvalho Fabio C.S. Nogueira Clovis Orlando Fonseca Júlio Cesar Thomé de Souza Silva Maria da Gloria Costa Carvalho Gilberto Barbosa Domont Nilson I. T. Zanchin Juliana de Saldanha da Gama Fischer A time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiforme Frontiers in Oncology Quantitative Proteomics Glioblastoma Multiforme mass spectrometry based proteomics molecular heterogeneity iTRAQ. |
author_facet |
Priscila Ferreira Aquino Paulo Costa Carvalho Paulo Costa Carvalho Fabio C.S. Nogueira Clovis Orlando Fonseca Júlio Cesar Thomé de Souza Silva Maria da Gloria Costa Carvalho Gilberto Barbosa Domont Nilson I. T. Zanchin Juliana de Saldanha da Gama Fischer |
author_sort |
Priscila Ferreira Aquino |
title |
A time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiforme |
title_short |
A time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiforme |
title_full |
A time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiforme |
title_fullStr |
A time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiforme |
title_full_unstemmed |
A time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiforme |
title_sort |
time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiforme |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2016-08-01 |
description |
Tumors consist of cells in different stages of transformation with molecular and cellular heterogeneity. By far, heterogeneity is the hallmark of glioblastoma multiforme (GBM), the most malignant and aggressive type of glioma. Most proteomic studies aim in comparing tumors from different patients, but here we dive into exploring the intratumoral proteome diversity of a single GBM. For this, we profiled tumor fragments from the profound region of the same patient’s GBM but obtained from two surgeries a year’s time apart. Our analysis also included GBM‘s fragments from different anatomical regions. Our quantitative proteomic strategy employed 4-plex iTRAQ peptide labeling followed by a four-step strong cation chromatographic separation; each fraction was then analyzed by reversed-phase nano-chromatography coupled on-line with an Orbitrap-Velos mass spectrometer. Unsupervised clustering grouped the proteomic profiles into four major distinct groups and showed that most changes were related to the tumor’s anatomical region. Our analysis revealed that most changes are related to the tumor’s anatomical region. Nevertheless, we report differentially abundant proteins from GBM’s fragments of the same region but obtained one year apart. We discuss several key proteins (e.g., S100A9) and enriched pathways linked with GBM such as the Ras pathway, RHO GTPases activate PKNs, and those related to apoptosis, to name a few. As far as we know, this is the only report that compares GBM fragments proteomic profiles from the same patient. Ultimately, our results fuel the forefront of scientific discussion on the importance in exploring the richness of subproteomes within a single tissue sample for a better understanding of the disease, as each tumor is unique. |
topic |
Quantitative Proteomics Glioblastoma Multiforme mass spectrometry based proteomics molecular heterogeneity iTRAQ. |
url |
http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00183/full |
work_keys_str_mv |
AT priscilaferreiraaquino atimebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT paulocostacarvalho atimebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT paulocostacarvalho atimebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT fabiocsnogueira atimebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT clovisorlandofonseca atimebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT juliocesarthomedesouzasilva atimebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT mariadagloriacostacarvalho atimebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT gilbertobarbosadomont atimebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT nilsonitzanchin atimebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT julianadesaldanhadagamafischer atimebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT priscilaferreiraaquino timebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT paulocostacarvalho timebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT paulocostacarvalho timebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT fabiocsnogueira timebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT clovisorlandofonseca timebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT juliocesarthomedesouzasilva timebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT mariadagloriacostacarvalho timebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT gilbertobarbosadomont timebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT nilsonitzanchin timebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme AT julianadesaldanhadagamafischer timebasedandintratumoralproteomicassessmentofarecurrentglioblastomamultiforme |
_version_ |
1725637506379022336 |